Gland Pharma Limited has approved the acquisition of 100% of the equity share capital of its step-down subsidiary, Gland Pharma USA Inc. The transaction, valued at USD 5,01,208, aims to streamline the corporate structure by making Gland US a direct wholly-owned subsidiary. This move is expected to remove multiple layers and enhance operational efficiency. The acquisition was considered and approved by the Board of Directors during their meeting on September 13, 2026, with completion anticipated by October 31, 2026.
Gland Pharma Streamlines Corporate Structure with US Subsidiary Acquisition
In a strategic move to simplify its organizational framework, Gland Pharma Limited announced the approval of acquiring 100% of the equity share capital of its step-down subsidiary, Gland Pharma USA Inc. (Gland US). This transaction, approved by the Board of Directors on September 13, 2026, will convert Gland US into a direct wholly-owned subsidiary of the Company. The acquisition is from Gland Pharma International Pte. Ltd., another wholly-owned subsidiary.
Rationale and Deal Details
The primary objective behind this acquisition is to remove multiple corporate layers and streamline the overall structure. While the acquisition is a related party transaction, it is being conducted on an arm’s length basis, with the consideration determined by an independent valuer. The cost of acquisition is reported as USD 5,01,208. The Company’s management has indicated that this change will not have a material impact on the business or operations of Gland Pharma.
Transaction Approvals and Timeline
The transaction has received prior approval from the Audit Committee and the Board of Directors, in line with the Companies Act, 2013. The announcement also notes that the acquisition is exempt from certain shareholder approval requirements due to its nature as a transaction between the Company and its wholly-owned subsidiary, where accounts are consolidated. Gland Pharma expects to complete the acquisition of Gland US equity shares by October 31, 2026.
Background of Gland US
Gland US is a wholly-owned step-down subsidiary operating in a similar line of business as the parent company. Its principal activity involves the marketing and distribution of pharmaceutical products. Incorporated on March 07, 2022, Gland US reported a turnover of USD 87,342 for FY25 and USD 4,83,808 for FY24, with no turnover reported for FY26. The entity has its presence in the United States of America.
Source: BSE
